Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in…
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in…
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU,…
Positions Curium as leading manufacturer of Lu-177 isotopeBrings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET…
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut…
Annual Recurring Revenue (ARR)⁽¹⁻²⁾ up 59% YoY to $71.1 millionTotal Revenue up 51% YoY to $20.6 millionAdjusted EBITDA ⁽²⁾ up…
2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory…
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of…
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical…
NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;…